• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊朗部分省份儿童接种麻疹、腮腺炎、风疹联合疫苗后的不良反应。

Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.

机构信息

Department of Pediatrics, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Arch Iran Med. 2011 Mar;14(2):91-5.

PMID:21361714
Abstract

BACKGROUND

Several adverse events following immunization (AEFI) have been attributed to immunization with live attenuated measles, mumps, and rubella (MMR) vaccines. The MMR vaccine was introduced into the routine infant immunization schedule in 2003, followed by a second dose of vaccine at school-entry for children 4 to 6 years of age. The objective of this study was to characterize adverse reactions following MMR vaccination in Iran.

METHODS

Children who received the MMR vaccine and resided in five selected provinces of Iran were examined weekly for four weeks to detect well-known AEFIs that included: parotitis, fever and convulsions, convulsions without fever, encephalopathy, and anaphylactic reactions. Incidence of AEFIs were calculated and compared among recipients in both age groups.

RESULTS

During the follow-up period, trained providers reported 792 AEFIs. Parotitis was the most frequent event occurring in 1.8% of recipients. Of 14,109 children vaccinated at 12 months of age the following AEFIs occurred: parotitis (147), fever and convulsions (8), convulsions (7), encephalopathy (1), and anaphylactic reactions (1). Of 29,338 children vaccinated at 4 to 6 years of age, parotitis, fever and convulsions, encephalopathy, and anaphylaxis occurred in 626, 5, 1, and 1 child, respectively; no convulsions without fever were reported in this age group.

CONCLUSION

Parotitis is the most frequent AEFI among MMR vaccine recipients in Iran. Incidence rates of AEFIs following MMR vaccination in Iran are similar to rates of AEFIs reported in other studies.

摘要

背景

有几种疫苗接种后不良反应(AEFI)归因于接种减毒麻疹、腮腺炎和风疹(MMR)疫苗。MMR 疫苗于 2003 年被纳入常规婴儿免疫接种计划,随后为 4 至 6 岁儿童在入学时接种第二剂疫苗。本研究的目的是描述伊朗 MMR 疫苗接种后的不良反应。

方法

在伊朗五个选定省份居住的接种 MMR 疫苗的儿童每周接受检查四周,以发现包括:腮腺炎、发热和惊厥、无热惊厥、脑病和过敏反应在内的已知 AEFI。计算并比较了两组接受者的 AEFI 发生率。

结果

在随访期间,经过培训的提供者报告了 792 例 AEFI。腮腺炎是最常见的事件,发生率为 1.8%。在 12 个月大时接种疫苗的 14109 名儿童中,发生了以下 AEFI:腮腺炎(147)、发热和惊厥(8)、惊厥(7)、脑病(1)和过敏反应(1)。在 4 至 6 岁接种疫苗的 29338 名儿童中,626 名、5 名、1 名和 1 名儿童分别出现腮腺炎、发热和惊厥、脑病和过敏反应;该年龄组未报告无热惊厥。

结论

腮腺炎是伊朗 MMR 疫苗接种者中最常见的 AEFI。伊朗 MMR 疫苗接种后 AEFI 的发生率与其他研究报告的 AEFI 发生率相似。

相似文献

1
Adverse reactions following immunization with MMR vaccine in children at selected provinces of Iran.伊朗部分省份儿童接种麻疹、腮腺炎、风疹联合疫苗后的不良反应。
Arch Iran Med. 2011 Mar;14(2):91-5.
2
Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign.与1998年澳大利亚麻疹控制运动相关的免疫接种后不良事件。
Commun Dis Intell. 2000 Feb 17;24(2):27-33.
3
Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.5至6岁健康儿童接种第二剂麻疹-腮腺炎-风疹-水痘疫苗的免疫原性和安全性
Pediatr Infect Dis J. 2007 Feb;26(2):153-8. doi: 10.1097/01.inf.0000250689.09396.21.
4
Adverse events associated with MMR vaccines in Japan.日本与麻疹、腮腺炎、风疹联合疫苗相关的不良事件。
Acta Paediatr Jpn. 1996 Jun;38(3):205-11. doi: 10.1111/j.1442-200x.1996.tb03471.x.
5
Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.9月龄健康儿童早期接种两剂四价麻疹-腮腺炎-风疹-水痘(MMRV)疫苗的安全性和免疫原性。
Infection. 2007 Oct;35(5):326-33. doi: 10.1007/s15010-007-6337-z. Epub 2007 Aug 20.
6
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.在15个月至2岁或2至6岁已接种麻疹-腮腺炎-风疹(MMR)疫苗的儿童中,接种麻疹-腮腺炎-风疹-水痘(MMRV)疫苗后再接种一剂水痘疫苗的免疫原性和安全性。
Vaccine. 2009 Jan 14;27(3):446-53. doi: 10.1016/j.vaccine.2008.10.064. Epub 2008 Nov 11.
7
Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.2007年至2013年澳大利亚维多利亚州免疫接种后的儿童过敏性不良事件。
Vaccine. 2015 Mar 24;33(13):1602-7. doi: 10.1016/j.vaccine.2015.02.008. Epub 2015 Feb 16.
8
Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.9月龄和15月龄时麻疹、腮腺炎和风疹疫苗的比较评估。
Indian J Med Res. 2003 Nov;118:183-6.
9
Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.在健康儿童生命的第二年,对一剂和两剂冰箱保存稳定的四价麻疹-腮腺炎-风疹-水痘疫苗后的免疫原性和安全性评估。
Pediatr Infect Dis J. 2008 Aug;27(8):724-30. doi: 10.1097/INF.0b013e318170bb22.
10
[Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine].冻干麻疹-腮腺炎-风疹联合减毒活疫苗的安全性和免疫原性研究
Zhonghua Liu Xing Bing Xue Za Zhi. 2002 Dec;23(6):435-7.

引用本文的文献

1
A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine.新型麻疹、腮腺炎、风疹(MMR)疫苗的安全性和免疫原性综述。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2302685. doi: 10.1080/21645515.2024.2302685. Epub 2024 Jan 18.
2
The characteristics and trend of adverse events following immunization reported by information system in Jiangsu province, China, 2015-2018.2015-2018 年中国江苏省免疫接种后不良反应信息系统报告的不良反应特征和趋势。
BMC Public Health. 2021 Jul 7;21(1):1338. doi: 10.1186/s12889-021-11387-3.
3
Does Food Allergy Require Any Change in Measles-Mumps-Rubella Vaccination?
食物过敏是否需要改变麻疹-腮腺炎-风疹联合疫苗的接种?
Indian J Pediatr. 2019 Oct;86(10):915-920. doi: 10.1007/s12098-019-02981-w. Epub 2019 May 18.
4
Hospital-based collaboration for epidemiological investigation of vaccine safety: A potential solution for low and middle-income countries?基于医院的疫苗安全性流行病学调查合作:中低收入国家的潜在解决方案?
Vaccine. 2018 Jan 8;36(3):345-346. doi: 10.1016/j.vaccine.2017.10.003. Epub 2017 Oct 21.
5
Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.增强全球疫苗药物警戒:含麻疹-腮腺炎疫苗接种后无菌性脑膜炎和免疫性血小板减少性紫癜的概念验证研究。
Vaccine. 2018 Jan 8;36(3):347-354. doi: 10.1016/j.vaccine.2017.05.012. Epub 2017 May 27.
6
Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.一种新型含埃德蒙斯顿-萨格勒布麻疹毒株、星野腮腺炎毒株和RA 27/3风疹毒株的冻干活MMR疫苗的免疫原性和安全性:一项随机、对照、活性对照III期临床试验结果
Hum Vaccin Immunother. 2017 Jul 3;13(7):1523-1530. doi: 10.1080/21645515.2017.1302629. Epub 2017 Mar 31.
7
Three cases of mumps virus and enterovirus coinfection in children with enteroviral meningitis.3例肠道病毒脑膜炎患儿合并腮腺炎病毒与肠道病毒感染
Medicine (Baltimore). 2016 Dec;95(49):e5610. doi: 10.1097/MD.0000000000005610.
8
International Consensus (ICON): allergic reactions to vaccines.国际共识(ICON):疫苗过敏反应
World Allergy Organ J. 2016 Sep 16;9(1):32. doi: 10.1186/s40413-016-0120-5. eCollection 2016.